Alterity Therapeutics Ltd has released a press release.
Appendix 4C - quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity receives a $4.8 million R&D Tax Incentive Refund
- European Orphan Designation granted for PBT434 for MSA
- AGM Presentation 2019
- Chairmans Address to Shareholders
- Lead drug candidate receives positive opinion from EMA
Later from Alterity Therapeutics
- NASDAQ Non-Compliance Notice Received
- NASDAQ Temporary Relief
- Appendix 4C and Quarterly Update
- Presentation on ATH434 to American Academy of Neurology
- Meeting with US FDA provides development path for ATH434
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics